Guatemala has signed confidentiality agreements with pharmaceutical companies and the World Health Organization (WHO) regarding the acquisition of COVID-19 vaccines. The country expects to receive the first 800,000 doses from mid-February onward through the COVAX program backed by the WHO.
COVAX is a global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level. In its mission to expedite early availability of vaccines and help bring a rapid end to the acute stage of the COVID-19 pandemic, COVAX exercises agreement options with several pharmaceutical companies.
Guatemala also expects vaccines from:
-Pfizer and BioNTech, which its vaccine BNT162b2 against SARS-CoV-2 has demonstrated evidence of efficacy in participants without prior evidence of SARS-CoV-2 infection
-Moderna, a biotechnology company founded in 2010 in Cambridge, Massachusetts, which is pioneering a class of medicines based on messenger RNA (mRNA).
-Russia’s Sputnik V, the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 20 countries.
The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers.
